{
    "address": "Karolinska Institutet Science Park, Fogdevreten 2",
    "city": "Solna",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W1R02C105",
    "description": "Asarina Pharma AB is a Swedish biotech company developing Sepranolone for allopregnanolonerelated stress, menstrual and neurological disorders. The company is headquartered in Solna, Stockholm and currently employs 4 full-time employees. The company went IPO on 2018-09-24. The Company\u2019s main product is Sepranolone, a treatment for Premenstrual dysphoric disorder (PDD), a form of Premenstrual syndrome (PMS). Sepranolone (UC1010) is an endogenous compound occurring naturally in the brain. Sepranolone inhibits the effects of allopregnanolone, the steroid that causes PMDD. Moreover, Sepranolone is applicable for treatment of menstrual migraine. Additionally to clinical trials with sepranolone, the Company develops a sepranolone analog that is a similar substance, which allows for alternative administration. The firm conducts trials in Europe. The Company\u2019s main shareholders are Kurma Biofund and The Foundation for Baltic and East European Studies.",
    "employeeTotal": "4.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Pharmaceuticals",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Pharmaceuticals",
    "gsector": "Health Care",
    "gsubind": "Pharmaceuticals",
    "ipo": "2018-09-24",
    "isin": "SE0011641794",
    "logo": "",
    "marketCapitalization": 62.51299,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in Biotechnology",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Asarina Pharma AB (publ)",
    "phone": "46852484482.0",
    "sedol": "BD5GZZ3",
    "shareOutstanding": 18.744524,
    "state": "STOCKHOLM",
    "ticker": "ASAP.ST",
    "weburl": "http://www.asarinapharma.com/"
}